Commercializing an MRI Breakthrough Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Development Costs: $40M invested in R&D to date (Paragraph 4).
Projected Unit Cost: $1.2M production cost per unit at scale (Exhibit 3).
Target Selling Price: $2.5M per unit (Exhibit 3).
Market Size: Estimated 400 new MRI installations globally per year in the premium segment (Paragraph 7).

Operational Facts

Technology: Proprietary superconducting magnet design reduces scan times by 60% (Paragraph 2).
Manufacturing: Current prototype facility capacity is 5 units per year. Scaling to 50 units/year requires $15M capital expenditure (Paragraph 12).
Regulatory: FDA approval pending; estimated 14 months to clearance (Paragraph 9).

Stakeholder Positions

CEO (Marcus Thorne): Favors aggressive market penetration to capture early-mover advantage.
CFO (Elena Rodriguez): Concerned about cash burn and debt-to-equity ratio if external funding is required.
Head of R&D (Dr. Aris): Emphasizes maintaining technical superiority over cost-cutting measures.

Information Gaps

Competitor response timeframes to the magnet design breakthrough.
Service and maintenance revenue projections post-installation.
Specific geographic regulatory hurdles beyond FDA (e.g., CE Mark).

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How should the firm commercialize its MRI technology to maximize long-term market share while managing the cash-flow constraints of a single-product medical device company?

Structural Analysis

Value Chain: The firm owns the IP but lacks the distribution and service network of incumbents (Siemens, GE).
Barriers to Entry: High. Regulatory hurdles and the requirement for clinical trust create significant moats.

Strategic Options

Option 1: Direct Entry (Build). Scale manufacturing and establish a direct sales force. Trade-off: High capital risk, full margin capture.
Option 2: Strategic Partnership (License). License technology to a major incumbent. Trade-off: Lower margin, immediate cash infusion, reduced brand control.
Option 3: Hybrid (Niche Focus). Partner for global distribution while retaining direct sales for top-tier research hospitals. Trade-off: Operational complexity, balanced risk.

Preliminary Recommendation

Pursue Option 3. Targeting research hospitals builds clinical credibility. Partnering for secondary markets mitigates the risk of failing to scale manufacturing, which is the firm’s primary operational weakness.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Month 1-6: Secure FDA clearance and finalize clinical trial data for marketing.
Month 7-12: Finalize partnership agreement with a Tier-2 medical distributor to handle logistics and service.
Month 13-18: Initial rollout to 5-10 flagship research institutions.

Key Constraints

Manufacturing Throughput: The $15M expansion is a binary risk; if demand exceeds capacity, the brand suffers.
Service Network: MRI machines require 24/7 support. Without a service partner, the firm cannot compete with incumbents.

Risk-Adjusted Implementation

The firm must avoid self-performing service. A contract with a third-party medical maintenance firm is required before the first unit ships. Contingency: If FDA approval slips by more than 3 months, the firm must pause the $15M factory expansion to preserve cash.

4. Executive Review and BLUF (Executive Critic)

BLUF

The firm is a technology company masquerading as a medical device manufacturer. Scaling manufacturing internally is a mistake. The company should immediately pursue a licensing agreement with a major incumbent for the global market while retaining the rights to sell directly to a select group of 20 top-tier research institutions. This preserves cash, avoids the service-network trap, and allows the firm to remain focused on its core competency: magnet innovation. If the company attempts to build a global sales and service organization, it will exhaust its capital and be acquired for pennies on the dollar by the very competitors it seeks to challenge.

Dangerous Assumption

The assumption that the firm can successfully build a global service and maintenance organization alongside a manufacturing ramp-up. It ignores the institutional trust incumbents enjoy.

Unaddressed Risks

Service Failure: A single 48-hour system downtime at a client site will destroy the firm’s reputation. Probability: High. Consequence: Fatal.
IP Leakage: Licensing technology risks exposing proprietary magnet designs to reverse engineering. Probability: Moderate. Consequence: High.

Unconsidered Alternative

A pure-play R&D exit. The firm could sell the IP to an incumbent today for an upfront payment plus royalties, avoiding all execution risk and capital expenditure.